Heart failure & cardiomyopathies
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Authors' conclusion
The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates.
Study context
- Population
- Patients with heart failure (HF) (heart failure with reduced ejection fraction (HFrEF) in DAPA-HF; HFmrEF/heart failure with preserved ejection fraction (HFpEF) in DELIVER)2 RCTs pooled
- Participants
- 11,007 patients
- Comparison
- Dapagliflozin vs placebo, by geographic region
- Europen = 5,159
- North American = 1,528
- South American = 1,998
- Asian = 2,322
- Outcome
- Worsening HF or CV death
Methodological detailssubgroup analysis by geographic region
- Subgroup analysis by geographic region
Pooled result
As reported in the abstract
Worsening HF or CV death, dapagliflozin vs placebo, by region
Dapagliflozin vs PlaceboHazard ratio (95% CI)
Europe
0.85(0.75–0.96)
North America
0.75(0.61–0.93)
South America
0.72(0.58–0.89)
Asia
0.74(0.61–0.91)
- Benefit not modified by region
- P for interaction = 0.40
Further pooled results
Primary outcome rate by region (per 100 person-years)
Effect modification by region within HFrEF and HFmrEF/HFpEF
- HFrEF: no modification by region
- P for interaction = 0.39
- HFmrEF/HFpEF: no modification by region
- P for interaction = 0.84
Safety
| Outcome | North America | South America |
|---|---|---|
| Discontinuation of randomised treatment (placebo) | 21.8% | 6.4% |
Discontinuation of randomised treatment (placebo)
- Discontinuation did not differ between placebo and dapagliflozin by region
Original publication
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. J Am Coll Cardiol. Published 21 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →